In the latest episode of The Psych Review Dave reviews esketamine use in the relapse prevention of treatment resistant depression, Shakira finds out that antidepressant doses may not need to be as high as you might have thought, and Mazz questions the usefulness of CT scanning in first episode psychosis.

The articles covered in this month's episode are:
- Dave: Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., ... & Thase, M. E. (2019). Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA psychiatry.
- Shak: Furukawa, T.A., Cipriani, A., et al. (2019). Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. The Lancet Psychiatry. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(19)30217-2/fulltext
- Mazz: Harris, G. et al. (2019). How often does computed tomography (CT) of the brain demonstrate a cause for psychosis? A 7-year retrospective study at a tertiary metropolitan hospital. Australasian Psychiatry, 27(2), pages 183-186 DOI: 10.1177/103985621881571

The Psych Review was brought to you by Call to Mind, a new telepsychiatry service that you can learn more about at www.calltomind.com.au. The original music in our podcast was provided by the very talented John Badgery, and our logo was designed by the creative genius of Naz.